Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 3/20 | 0.35 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.35 |
| ▸ | CHAT | P28329 | 2/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22708739 | 1.00 | AURKA (0.37) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL22709177 | 0.96 | VNN1 (0.34) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL18818944 | 0.96 | VNN1 (0.34) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL20334094 | 0.96 | VNN1 (0.34) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL22708806 | 0.93 | AURKA (0.35) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL23477174 | 0.92 | AURKA (0.37) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL18811320 | 0.92 | AURKA (0.37) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL21515142 | 0.92 | AURKA (0.37) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL22695663 | 0.92 | AURKA (0.38) | AURKAEP300NAA50CHATKAT5 | |
| SCHEMBL20333686 | 0.92 | AURKA (0.38) | AURKAEP300NAA50CHATKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |